{"id":21051,"date":"2019-01-15T00:00:00","date_gmt":"2019-01-15T05:00:00","guid":{"rendered":"https:\/\/genomequebec.com\/coporative-contents\/breast-cancer-researchers-develop-the-most-accurate-risk-prediction-model-to-date\/"},"modified":"2023-04-17T10:49:18","modified_gmt":"2023-04-17T14:49:18","slug":"breast-cancer-researchers-develop-the-most-accurate-risk-prediction-model-to-date","status":"publish","type":"coporative-content","link":"https:\/\/genomequebec.com\/en\/coporative-contents\/breast-cancer-researchers-develop-the-most-accurate-risk-prediction-model-to-date\/","title":{"rendered":"Breast Cancer – Researchers develop the most accurate risk-prediction model to date"},"content":{"rendered":"

Qu\u00e9bec City, January 15, 2019<\/strong> \u2013 A simple saliva test could help to gauge, with unprecedented accuracy, a woman\u2019s risk of developing breast cancer during her lifetime, according to an international study published today involving researchers from Universit\u00e9 Laval and the CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center. By combining a person\u2019s genetic profile obtained through a saliva sample with a statistical model that takes into account family history, hormonal factors and lifestyle habits, the researchers were able to estimate each woman\u2019s overall risk for breast cancer, paving the way for personalized screening protocols for the disease.<\/p>\n

\u00a0<\/p>\n

\u201cMany hundreds of researchers around the world pooled the DNA samples they had collected through their respective projects and conducted genomic analyses on 94,000 women who had had breast cancer and another 75,000 women who were part of a control group,\u201d explains one of the study\u2019s leaders, Jacques Simard, Canada Research Chair in Oncogenetics at Universit\u00e9 Laval and researcher at the Genomics Center of the CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center. Through sophisticated statistical analyses, we developed a breast cancer risk score that includes 313 genetic variants and then validated it on nearly 220,000 women.\u201d<\/p>\n

\u00a0<\/p>\n

Breast cancer screening in Qu\u00e9bec and Canada is primarily conducted using mammography and generally targets women aged\u00a050 to 69. Despite this prevention-based approach, however, many women at high risk for the disease slip through the cracks. The model developed by Professor Simard and his colleagues will contribute to a more personalized approach to breast cancer screening based on individual risk. \u201cUsing our model, it will be possible to predict each woman\u2019s individual risk and offer her a personalized screening protocol, regardless of her age,\u201d said the researcher. \u201cAll we will need is a single saliva sample collected from a woman when she reaches her early forties.\u201d<\/p>\n

\u00a0<\/p>\n

How long before the model can be adopted by the health care system? <\/strong><\/p>\n

A team spearheaded by Jacques Simard is currently working on a pre-implementation project for this model among 10,000 women in Qu\u00e9bec and Ontario. \u201cOur goal is to evaluate the acceptability, feasibility and efficiency of risk-based screening. We also want to study the organizational challenges involved in integrating personalized screening into our health care system, as well as the costs and anticipated benefits,\u201d said the researcher.<\/p>\n

\u00a0<\/p>\n

This pre-implementation initiative received $15.2\u00a0million in funding from G\u00e9nome Qu\u00e9bec, Genome Canada, the Canadian Institutes of Health Research, the Quebec Breast Cancer Foundation, the Ontario Research Fund and other partners. For more information on the researchers involved in this international multidisciplinary project<\/a>, visit the G\u00e9nome Qu\u00e9bec website.<\/p>\n

\u00a0<\/p>\n

Details of the breakthrough were published today in Genetics in Medicine<\/em><\/a> and recently in The American Journal of Human Genetics<\/em><\/a>.<\/p>\n

\u00a0<\/p>\n","protected":false},"featured_media":0,"template":"","corporative_content_category":[376],"class_list":["post-21051","coporative-content","type-coporative-content","status-publish","hentry","corporative_content_category-press-releases"],"acf":[],"_links":{"self":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/coporative-content\/21051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/coporative-content"}],"about":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/types\/coporative-content"}],"wp:attachment":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/media?parent=21051"}],"wp:term":[{"taxonomy":"corporative_content_category","embeddable":true,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/corporative_content_category?post=21051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}